|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | CONSORT 2010说明与详述:报告平行对照随机临床试验指南的更新显示文摘大量证据显示随机对照临床试验(randomised controlled trial,RCT)的报告质量不理想。报告不透明,则读者既不能评判试验结果是否真实可靠,也不能从中提取可用于系统综述的信息。最近的方法学分析表明,报告不充分和设计不合理与对治疗效果产生评价偏倚有关。这种系统误差对RCT损害严重,而RCT正是以其能减少或避免偏倚而被视为评价干预措施的金标准。为了提高RCT的报告质量,一个由专家和编辑组成的工作组制定了临床试验报告的统一标准(Consolidated Standards of Reporting Trials,CONSORT)声明。CONSORT声明于1996年首次发表,并于2001年更新。声明由对照检查清单和流程图组成,供作者在报告RCT时使用。许多核心医学期刊和主要国际性编辑组织都已认可CONSORT声明。该声明促进了对RCT的严格评价和解释。2001年,在对CONSORT进行修订时,人们就已经清楚地认识到,解释和说明制定CONSORT声明的原理,有助于研究人员等撰写或评价临床试验报告。一篇CONSORT说明与详述文章于2001年同2001版CONSORT声明一起发表。2007年1月的专家会议之后,对CONSORT声明作了进一步修订并已发表,即'CONSORT2010声明'。这次更新对原版对照检查清单作了文字上的修改,使其更为明晰,并收入了与一些新近才认识到的主题相关的建议,如选择性报告结局产生的偏倚。说明与详述文件旨在加强人们对CONSORT声明的理解、应用和传播,这次也作了大量修订,对每一项新增或更新的清单条目的含义和增改理由进行了解释,提供了优秀的报告实例,还尽可能地提供了相关的经验性研究的参考文献。文中收入了若干流程图实例。'CONSORT2010声明'、其说明与详述文件,以及相关网站(www.consort-statement.org),对于改进随机临床试验报告必将有所裨益。 | David Moher Sally Hopewell Kenneth F Schulz Victor Montori Peter C Gφtzsche P J Devereaux Diana Elbourne Matthias Egger Douglas G Altman 周庆辉 卞兆祥 刘建平 | 2010 | 中西医结合学报2010，8，8： | 318 |
| 2 | 中国妇女妊娠前后单纯服用叶酸对神经管畸形的预防效果显示文摘目的 评价妇女在妊娠前后服用单纯 40 0 μg叶酸增补剂对胎 /婴儿神经管畸形 (NTDs)的预防效果。方法 1993~ 1995年在中国北方的NTDs高发地区和南方的NTDs低发地区妇女增补叶酸的推广项目中 ,共募集从孕前或孕后任何时间开始服药的妇女 130 142名 ,未服药的妇女 1176 89名 ;设计的服药方法从婚检时开始到孕满 3个月为止 ,每天服用单纯叶酸片 40 0 μg ;最后对妇女的分娩结局进行监测并进行预防效果的对比评价研究。结果 服药组妇女生育的胎婴儿中共发现 10 2例NTDs ,对照组胎婴儿中共发现 173例NTDs。末次月经前募集的未服药妇女在孕 2 0周以后分娩的胎婴中NTDs发生率 ,北方为 4 8‰ (16 / 3 318) ,南方为 1 0‰ (2 8/ 2 82 6 5 ) ,而妊娠前后服药妇女组则分别为1 0‰ (13/ 13 0 12 )和 0 6‰ (34/ 5 86 38)。与末次月经前募集的未服药妇女组相比 ,北方服药妇女NTDs发生率明显降低 ,其中依从性大于 80 %的服药组妇女预防率达 85 % (95 %CI为 6 2 %~ 94% ) ,南方地区服叶酸的预防率为 41% (95 %CI为 3 %~ 6 4% )。结论 妇女在妊娠前后每天服用单纯叶酸 40 0 | 李竹 RobertJ Berry 李松 J David Erickson 王红 Cynthia A Moore 赵平 Joseph Mulinare 洪世欣 Lee-Yang C Wong 呼和牧人 Jacqueline Gindler 郝玲 Adolfo Correa 朱慧萍 Elaine Gunter | 2000 | 中华医学杂志2000，80，7： | 185 |
| 3 | BCLC策略:预后预测和治疗推荐2022版更新显示文摘2018版BCLC预后和治疗推荐策略发布后,肝细胞癌(简称HCC)的研究又取得了重大进展。本次更新基于肝癌各领域的研究进展结果。重点关注影响策略的重要研究进展。虽然近年的研究结果成绩斐然,但将其引入为临床医生和研究者提供行动依据的循证模型指南来说证据效力依然不够确切。本文对该问题进行分析,阐述了为HCC患者制定个体化治疗临床决策所需的批判性思维和专业知识。 | Reig M Forner A Rimola J Ferrer-Fabrega J Burrel M Garcia-Criado A Kelley RK Galle PR Mazzaferro V Salem R Sangro B Singal AG Vogel A Fuster J Ayuso C Bruix J 刘永凡(摘译) 崔笑(摘译) 耿小平(审校) | 2022 | 肝胆外科杂志2022，30，5： | 80 |
| 4 | Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.显示文摘 | Abrey LE Batchelor TT Ferreri A J Gospodarowicz M Pulczynski EJ Zucca E Smith JR Korfel A Soussain C DeAngelis LM Neuwelt EA O′Neill BP Thiel E Shenkier T Graus F van den Bent M Seymour JF Poortmans P Armitage JO Cavalli F | 2005 | 中国神经肿瘤杂志2005，3，3： | 53 |
| 5 | MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes显示文摘 | Li Y Guessous F Zhang Y Dipierro C Kefas B Johnson E Marcinkiewicz L Jiang J Yang Y Schmittgen TD Lopes B Schiff D Purow B Abounader R | 2009 | 中国神经肿瘤杂志2009，7，4： | 56 |
| 6 | 初级保健中原发性醛固酮增多症的患病率和临床表现显示文摘原发性醛固酮增多症(primaryaldosteronism,PA)是一种异质性疾病,以高血压和相对自主于肾素血管紧张素系统产生过量醛固酮为特征。与心血管病风险相似的原发性高血压患者相比,PA患者发生心脑血管并发症的风险以及代谢综合征患病率增加,提示正确诊断PA的重要性。 | Monticone S Burrello J Tizzani D Bertello C Viola A Buffolo F Gabetti L Mengozzi G Williams TA Rabbia F Veglio F Mulatero P 练桂丽 叶鹏 | 2017 | 中华高血压杂志2017，25，5： | 58 |
| 7 | 文献快报(8):美国儿科学会颁布新版儿童青少年高血压筛查与管理临床实践指南显示文摘美国儿科学会于2017年8月重新颁布了《儿童青少年高血压筛查与管理临床实践指南》(以下简称《新指南》),主要涉及了新的规范血压图表、筛查方案修订和启动药物降压治疗的推荐,此外指南还对儿童血压偏高和高血压筛查时间及动态血压监测进行了推荐。为促进儿科临床诊疗中血压偏高的早期发现,《新指南》纳入了简化表格用于筛查。以舒张压和收缩压的第90百分位值作为筛查阳性标准,需要进一步开展听诊器袖套方法确诊。 | FLYNN J T KAELBER D C BAKER-SMITH C M 孙莹 | 2017 | 中国学校卫生2017，38，10： | 57 |
| 8 | Pyogenic liver abscess:An audit of 10 years’experience显示文摘AIM:To describe our own experience with pyogenic liver abscesses over the past 10 years and investigate the risk factors associated with failure of initial percutaneous therapy.METHODS:A retrospective study of records of 63 PLA patients presenting between 1998 and 2008 to Australian tertiary referral centre,were reviewed.Amoebic and hydatid abscesses were excluded.Demographic,clinical,radiological,and microbiological characteristics,as well as surgical/radiological interventions,were recorded.RESULTS:Sixty-three patients(42 males,21 females) aged 65(±14) years[mean±(SD) ]had prodromal symptoms for a median(interquartile range;IQR) of 7(5-14) d.Only 59%of patients were febrile at presentation;however,the serum C-reactive protein was elevated in all 47 in whom it was measured.Liver function tests were non-specifically abnormal.67%of patients had a solitary abscess,while 32%had>3 abscesses with a median(IQR) diameter of 6.3(4-9) cm.Causative organisms were:Streptococcus milleri 25%,Klebsiella pneumoniae 21%,and Escherichia coli 16%.A presumptive cryptogenic cause was most common (34%).Four patients died in this series:one from sepsis,two from advanced cancer,and one from acute myocardial infarction.The initial procedure was radiological aspiration±drainage in 54 and surgery in two patients.17%underwent surgical management during their hospitalization.Serum hypoalbuminaemia[mean (95%CI) :32(29-35) g/L vs 28(25-31) g/L,P=0.045] on presentation was found to be the only factor related to failure of initial percutaneous therapy on univariate analysis.CONCLUSION:PLA is a diagnostic challenge,because the presentation of this condition is non-specific.Intravenous antibiotics and radiological drainage in the first instance allows resolution of most PLAs;However,a small proportion of patients still require surgical drainage. | Tony CY Pang Thomas Fung Jaswinder Samra Thomas J Hugh Ross C Smith | 2011 | World Journal of Gastroenterology2011，17，12： | 46 |
| 9 | AGNP精神科治疗药物监测共识指南:2011显示文摘治疗药物监测(Therapeutic drug monitoring,TDM),如通过定量测定血清或血浆药物浓度指导用药剂量优化,已经成为对患者进行精神药物治疗的很有价值的工具。在患者用药依从性难以判断、药物耐受性不佳、治疗剂量下无效以及可能存在药代动力学药物-药物相互作用等情况下,测定药物浓度是很有用的。在精神科,有可能明显获益于TDM的主要患者群体包括儿童、孕妇、老年患者、智力障碍患者、涉及司法的患者、已知或怀疑携带药代动力学相关基因变异的患者,以及合并躯体疾病影响药代动力学的患者。然而,只有将TDM充分整合到临床治疗过程中去,才能发挥其优化药物治疗的潜在优势。为了促进TDM的合理应用,神经精神药理学与药物精神病学协会(Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie,AGNP)的TDM专家组在2004年发表了精神药物治疗药物监测指南。之后,随着知识不断更新,又有许多可能需要进行TDM的新药上市。因此,本次更新将神经精神药物的种类扩展到了128种,并将其TDM必要性划分为从'强烈推荐'到'可能有用'的四个等级。经过大量细致且全面的文献检索与分门别类的汇总整理,将基于循证医学理念的'治疗参考浓度范围'和'剂量相关参考浓度范围'呈现给大家。本共识指南引入了'实验室警戒浓度'的新概念,即实验室需要马上告知治疗医生的药物浓度上限。本共识指南还给出了诸如药物作为细胞色素P450酶的底物和抑制剂的性质,代谢物与母药浓度比值的常见范围,以及与结果解释相关的内容,还提供了何时将TDM与遗传药理学检测相结合的建议。遵循本指南,有助于改善许多患者精神药物治疗的效果,特别是那些存在药代动力学异常的患者。TDM是一门交叉学科,有时针对看起来不一致的数据,需要多学科坦诚地讨论,只有这样,患者才能从这种合作中获益。 | Hiemke C Baumann P Bergemann N Conca A Dietmaier O Egberts K Fric M Gerlach M Greiner C Gründer G Haen E Havemann-Reinecke U Jaquenoud Sirot E Kirchherr H Laux G Lutz UC Messer T Müller MJ Pfuhlmann B Rambeck B Riederer P Schoppek B Stingl J Uhr M Ulrich S Waschgler R Zernig G 李文标(译) 果伟(译) 阮灿军(译) 贺静(译) 汤宜朗(审校) 王传跃(审校) | 2016 | 实用药物与临床2016，19，10： | 37 |
| 10 | Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer显示文摘Inflammatory bowel diseases are characterised by inflammation that compromises the integrity of the epithelial barrier. The intestinal epithelium is not only a static barrier but has evolved complex mechanisms to control and regulate bacterial interactions with the mucosal surface. Apical tight junction proteins are critical in the maintenance of epithelial barrier function and control of paracellular permeability. The characterisation of alterations in tight junction proteins as key players in epithelial barrier function in inflammatory bowel diseases is rapidly enhancing our understanding of critical mechanisms in disease pathogenesis as well as novel therapeutic opportunities. Here we give an overview of recent literature focusing on the role of tight junction proteins, in particular claudins, in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer. | Jonathan Landy Emma Ronde Nick English Sue K Clark Ailsa L Hart Stella C Knight Paul J Ciclitira Hafid Omar Al-Hassi | 2016 | World Journal of Gastroenterology2016，22，11： | 39 |
| 11 | Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration.显示文摘 | Zhao W Liu H Liu W Wu Y Chen W Jiang B Zhou Y Xue R Luo C Wang L Jiang JD Liu J | 2006 | 中国生物学文摘2006，20，4： | 31 |
| 12 | 单轴压缩试验测定完整岩石应力-应变全曲线ISRM建议方法草案显示文摘 | Fairhurst C E Hudson J A | 2000 | 岩石力学与工程学报2000，19，6： | 34 |
| 13 | Chronic hepatitis B infection in pregnancy显示文摘There are no standard guidelines to follow when a patient with chronic hepatitis B infection becomes pregnant or desires pregnancy. Topics to consider include which patients to treat, when to start treatment, what treatment to use and when to stop treatment. Without any prophylaxis or antiviral therapy, a hepatitis B surface antigen and E antigen positive mother has up to a 90% likelihood of vertical transmission of hepatitis B virus(HBV) to child. Standard of care in the United States to prevent perinatal transmission consists of administration of hepatitis B immune globulin and HBV vaccination to the infant. The two strongest risk factors of mother to child transmission(MTCT) of HBV infection despite immunoprophylaxis are high maternal HBV viral load and high activity of viral replication. The goal is to prevent transmission of HBV at birth by decreasing viral load and/or decreasing activity of the virus. Although it is still somewhat controversial, most evidence shows that starting antivirals in the third trimester is effective in decreasing MTCT without affecting fetal development. There is a growing body of literature supporting the safety and efficacy of antiviral therapies to reduce MTCT of hepatitis B. There are no formal recommendations regarding which agent to choose. Tenofovir, lamivudine and telbivudine have all been proven efficacious in decreasing viral load at birth without known birth defects, but final decision of which antiviral medication to use will have to be determined by physician and patient. The antivirals may be discontinued immediately if patient is breastfeeding, or within first four weeks if infant is being formula fed. | Jennifer R Lamberth Sheila C Reddy Jen-Jung Pan Kevin J Dasher | 2015 | World Journal of Hepatology2015，7，9： | 32 |
| 14 | Arginase-1:一种新的肝细胞和肝细胞肿瘤的标记物显示文摘 | Yang B C Gong C Song J 黄文斌(摘译) | 2010 | 临床与实验病理学杂志2010，26，5： | 27 |
| 15 | 急性缺血性卒中的血管内治疗:神经介入外科学学会实践标准委员会的报告显示文摘目的总结采用血管内技术治疗急性缺血性卒中的有关证据并等级分类。方法对美国心脏协会(American Heart Association,AHA)以前发表的推荐意见进行审查并作为当前流程的基础。在此这基础上,进行系统的文献回顾以评估支持急性缺血性卒中血管内治疗的证据。根据AHA卒中委员会和牛津大学循证医学中心提出的循证医学证据分级指南进行评估。对操作安全性、技术效果以及对临床转归的影响进行特别审核。 | K A Blackham P M Meyers T A Abruzzo F C Alberquerque D Fiorella J Fraser D Frei C D Gandhi D V Heck J A Hirsch D P Hsu M Jayaraman S Narayanan C Prestigiacomo J L Sunshine 包元飞(译) 李永坤(译) 刘新峰(译) | 2012 | 国际脑血管病杂志2012，20，12： | 28 |
| 16 | 血管内超声去肾交感神经术治疗高血压:一项多中心,国际,单盲,随机,假手术对照试验显示文摘早期研究表明,基于射频的去肾交感神经术可降低中度高血压患者的血压。研究者研究了在没有使用抗高血压药物的情况下,使用血管内超声去。肾交感神经术是否会降低高血压患者的动态血压。 | 刘青 叶鹏 Azizi M Schmieder RE Mahfoud F Weber MA Daemen J Davies J Basile J Kirtane AJ Wang Y Lobo MD Saxena M Feyz L Rader F Lurz P Sayer J Sapoval M Levy T Sanghvi K Abraham J Sharp ASP Fisher NDL Bloch MJ Reeve-Stoffer H Coleman L Mullin C Mauri L | 2018 | 中华高血压杂志2018，26，10： | 27 |
| 17 | Pediatric functional constipation treatment with Bifi dobacterium-containing yogurt:A crossover,double-blind,controlled trial显示文摘AIM: To evaluate the treatment of pediatric functional chronic intestinal constipation (FCIC) with a probiotic goat yogurt. METHODS: A crossover double-blind formula-controlled trial was carried out on 59 students (age range: 5-15 years) of a public school in Belo Horizonte, MG, Brazil, presenting a FCIC diagnostic, according to Roma Ⅲ criteria. The students were randomized in two groups to receive a goat yogurt supplemented with 109 colony forming unit/mL Bifidobacterium longum (B.longum) (probiotic) daily or only the yogurt for a period of 5 wk (formula). Afterwards, the groups were intercrossed for another 5 wk. Defecation frequency, stool consistency and abdominal and defecation pain were assessed.RESULTS: Both treatment groups demonstrated improvement in defecation frequency compared to baseline. However, the group treated with probiotic showed most signif icant improvement in the f irst phase of the study. An inversion was observed after crossing over, resulting in a reduction in stool frequency when this group was treated by formula. Probiotic and formula improved stool consistency in the f irst phase of treatment, but the improvement obtained with probiotic was significantly higher (P = 0.03). In the second phase of treatment, the group initially treated with probiotic showed worseningstool consistency when using formula. However, the difference was not signif icant. A signif icant improvement in abdominal pain and defecation pain was observed with both probiotic and formula in the first phase of treatment, but again the improvement was more signif icant for the group treated with B. longum during phase I (P < 0.05). When all data of the crossover study were analyzed, significant differences were observed between probiotic yogurt and yogurt only for defecation frequency (P = 0.012), defecation pain (P = 0.046) and abdominal pain (P = 0.015). | Paula VP Guerra Luiza N Lima Tassia C Souza Vanessa Mazochi Francisco J Penna Andreia M Silva Jacques R Nicoli Elizabet V Guimares | 2011 | World Journal of Gastroenterology2011，17，34： | 25 |
| 18 | Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: Results of a multicent显示文摘AIM: Anti-Saccharomyces cerevisiae antibodies (ASCA), anti-nuclear associated anti-neutrophil antibodies (NANA) and antibodies to exocrine pancreas (PAB), are serological tools for discriminating Crohn’s disease (CrD) and ulcerative colitis (UC). Like CrD, coeliac disease (CoD) is an inflammatory bowel disease (IBD) associated with (auto) antibodies. Performing a multicenter study we primarily aimed to determine the performance of ASCA, NANA and PAB tests for IBD diagnosis in children and adults, and secondarily to evaluate the prevalence of these markers in CoD. METHODS: Sera of 109 patients with CrD, 78 with UC, 45 with CoD and 50 healthy blood donors were retrospectively included. ASCA, NANA and PAB were detected by indirect immunofluorescence (IIF). RESULTS: ASCA+/NANA- profile displayed a positive predictive value of 94.2% for CrD. Detection of ASCA was correlated with a more severe clinical profile of CrD and treatment of the disease did not influence their serum levels. ASCA positivity was found in 37.9% of active CoD.PAB were found in 36.7% CrD and 13.3% CoD patients and were not correlated with clinical features of CrD, except with an early onset of the disease. Fifteen CrD patients were ASCA negative and PAB positive. CONCLUSION: ASCA and PAB detected by IIF are specific markers for CrD although their presence does not rule out a possible active CoD. The combination of ASCA, NANA and PAB tests improves the sensitivity of immunological markers for CrD. Repeating ASCA, NANA, and PAB testing during the course of CrD has no clinical value. | S Desplat-Jégo C Johanet A Escande J Goetz N Fabien N Olsson E Ballot J Sarles JJ Baudon JC Grimaud M Veyrac P Chamouard RL Humbel | 2007 | World Journal of Gastroenterology2007，13，16： | 24 |
| 19 | Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death显示文摘 | Jiang H Gomez-Manzano C Aoki H Alonso MM Kondo S McCormick F Xu J Kondo Y Bekele BN Colman H Lang FF Fueyo J | 2007 | 中国神经肿瘤杂志2007，5，3： | 24 |
| 20 | NLRP3炎症小体对急性胰腺炎小鼠全身炎症反应及代偿性抗炎反应综合征的调节作用显示文摘【据《Gastroenterology》2019年10月报道】题:NLRP3炎症小体对急性胰腺炎小鼠全身炎症反应及代偿性抗炎反应综合征的调节作用(作者Sendler M等)胰腺炎开始时主要是无菌的局部炎症,其引起全身性炎症反应综合征(SIRS),然后是代偿性抗炎反应综合征(CARS)。来自德国格赖夫斯瓦尔德大学的Sendler等通过研究探讨了小鼠和人类血清中该过程的机制。 | 李德钊 郭晓林 SENDLER M van den BRANDT C GLAUBITZ J | 2020 | 临床肝胆病杂志2020，36，3： | 24 |
您所在的机构暂未开通此部分的功能，请联系管理员